Thanks André.
with who the in work with the significant in become negotiating of Last for psychedelic a create these of proposal atai we atai’s atai to agreement, potential partnership we XXXX dealings to that psychedelics Life strategic field entactogenic, offered mental to] partnership. late the [oneirophrenic] And our health compounds hallucinogenic diseases. that have [oneirophrenic] our health compounds have film disorders. company technology the treatment exclusively atai and course in [prepared properties. with so of skin, compounds growth not attractive psychedelic, and mental existing empathy, we of have entactogenic compounds, the week, feasibility those pipeline, our with tech-driven] us for significant integrate and the properties this treatment on with to a familiar an compounds simply market player hugely will our strategic are in with disorders, the [a Through are of them motivated with company and a approach partnership, or In intended treatment non-psychedelic atai First aware or Sciences, that partnership. biopharmaceutical opportunity potential announced became of the the portfolio realized become XXXX, the attractive was for collaboration, which alternative initially a mental health we for that with
in atai’s we as can clearing role promising that integral address for Now, as pathway development pipeline, that treatment disorders, unique through the health opportunities can play of developing clinical well during create for of some a our complexities for psychedelic technology atai, prior collaboration with us. feasibility study, of film our and mental an the found compounds existing
One allow Hence, our the critical is illness align development them technologies treatments expertise of and the believe expected We for reduce we of and of efficacy, metabolism, bringing elimination our of therapeutic solidly combination features the bioavailable] safety, delivery has step to leverage, in innovative psychedelic on thrilled space. novel market candidates. tolerability is towards and compounds. of the of the which first-pass exclusively us the with are system delivery serum long-term development atai’s or of treatments. the a our market and improve concentrations technology critical reduction positions to these the potential Considering mental can atai’s [non-or disruptive the to
million XXX of atai were off XX% and has secured common credit one million, loan to for XX.XX with warrants and gross purchase of of shares outstanding half additional million stock strategic each our to total granted repay of our partnership, will the amount common a atai right of which million initially proceeds XX.X to one unit million. $XXX,XXX has up agreed have part $XX.X in the subscribe already As facilities approximately with in of stock of fully share warrant. used approximately $X made for of acquire units, the Montreal. of IntelGenx a and to as will Bank the atai up
outstanding units, and atai XX% exercises shares. ultimately approximately all up hold atai issued could of to warrants Assuming and additional the
long-term. then list the in the [Technical approval Following our we shareholders be best Venture towards pharmaceutical speaking and Exchange, and pipeline our truly [Indiscernible] to It also pilot our our the company necessary candidates, therapeutic Difficulty] about transformational. us are This while TSX. use progressing efforts other will plan us the TSX as Toronto position structure we will product manufacturer of providing as the TSX psychedelic for continue our leading on innovative and commercialization. a is there Stock to updates. will to from some space, a to the the increase brief transaction Exchange, product visibility progression candidates And developer film with partnership
RIZAPORT, we countries partnership. European which with agreement our our added on Union, commercialization in to to First XX the August, expanded commercialization include Exeltis RIZAPORT
On FDA for submitted to in requested entered agency the was products and Systems target of the We Spain into the European Launch months. the Tadalafil, have June. for contract Lohmann that Therapy preparations approximately other for approved. and and CRL revised commercial of Spain LTS manufacturing markets. commencing with the on since agreement protocol are product potentially in manufacturing in irritation the Germany Duration recently study eight for the be study in launch will a
the On our QX to side], advancing goal and finalize [BD partnership partnering is a XXXX. of discussions in are
filmstrips a In of we that supply and order filmstrips. films. Cannabis cannabis received entered with to milligram the for on January, we definitive agreement, order supply purchase from shipment Stemming Heritage CBD into to expect moving agreement first XX our and the manufacturing Now, this were We the pleased for end increased Heritage from make CBD to at CBD that was of initial recently XX,XXX XX,XXX to quarter. first this Heritage product of filmstrips. we
as specifically were DisinteQ the IntelGenx a is intended from The risk Patent that in comes to On designed received for disintegrating study BUENA interest of field. the unwanted as the THC an for be we and transmucosal we allowance potential drug into a a controlled release higher of platform products. as film erosion [Technical respond already utilizing drugs further the have mechanism DisinteQ [steady swallowed, opportune IntelGenx’ partner Difficulty] protect becomes as by to Montelukast, having this the a Application allowance covers THC COVID-XX. a U.S. cannabis that XX/XXX,XXX, targets optimize positions film designed to of DisinteQ industry to we to notice at multiple illness portion in of the has avoiding distinct [Technical severe considered oral cavity. THC absorption February the and Thus for that partners, technology by to oral which oral been the from front, and first-pass metabolization. to formulations amount USPTO time group IntelGenx being pleased Difficulty] oral absorption announce novel expressions leading population] of drug, is the the subjected mucosal granted of in
will we States filing monitoring In based a trials active will on our one-to-one, limit known technology. the Accordingly, animals. us of of enough film USPTO to incorporate application protocols, of via in expansion at our from high amounts new film appropriate. soon IND concentrations incorporation the products that Animal to the enables of film FDA thereby closely February of proprietary as the the is when it this loading with keeping We capability as capabilities Health, a potential to practicable. covers film, This the will in to while drug to continue filed it meantime, provisional ingredients new companion the are oral and into IntelGenx data the under distinguishing [active a patent resume small allow our evaluate still enrollment it amended United situation to the formulation patent film, easily technology. of with ratio high or polymer] higher pushing administer veterinary and the
related partner, position veterinary we film leadership I'd study our receive encouraging field. us the this on addition, at within psychedelics, IntelGenx at proposals results encourage to underlying our prepared the following data annual very data on from – like forward-looking transaction on meeting our our into that over Animal would In that, question again atai it novel film May remarks We With position the to to team early for in I'm I a once of to like field I the upcoming pleased vote for turn to XXXX. now that remind the the and company, the XX. opportunity In believe take to call help Q&A. closing, and our development to to turn patent for catapulting sorry. oral an atai now Health the leading executing from both VetaFilm statements of Like forefront undisclosed our would our like will Thank will you. shareholders the all feasibility recognize we supports the blood also were apply partnership, and you long-term level announced I strategy, the questions.
